TREATMENT WITH INDINAVIR, ZIDOVUDINE, AND LAMIVUDINE IN ADULTS WITH HUMAN IMMUNODEFICIENCY VIRUS INFECTION AND PRIOR ANTIRETROVIRAL THERAPY

ROY M. GULICK, M.D., M.P.H., JOHN W. MELLORS, M.D., DIANE HAVLIR, M.D., JOSEPH J. ERON, M.D., CHARLES GONZALEZ, M.D., DEBORAH McMAHON, M.D., DOUGLAS D. RICHMAN, M.D., FRED T. VALENTINE, M.D., LESLIE JONAS, B.S., ANNE MEIBOHM, PH.D., EMILIO A. EMINI, PH.D., AND JEFFREY A. CHODAKEWITZ, M.D.

ABSTRACT

Background The new protease inhibitors are potent inhibitors of the human immunodeficiency virus (HIV), and in combination with other antiretroviral drugs they may be able to cause profound and sustained suppression of HIV replication.

Methods In this double-blind study, 97 HIV-infected patients who had received zidovudine treatment for at least 6 months and had 50 to 400 CD4 cell counts per cubic millimeter and at least 20,000 copies of HIV RNA per milliliter were randomly assigned to one of three treatments for up to 52 weeks: 800 mg of indinavir every eight hours; 200 mg of zidovudine every eight hours combined with 150 mg of lamivudine twice daily; or all three drugs. The patients were followed to monitor the occurrence of adverse events and changes in viral load and CD4 cell counts.

Results The decrease in HIV RNA over the first 24 weeks was greater in the three-drug group than in the other groups (P<0.001 for each comparison). RNA levels decreased to less than 500 copies per milliliter at week 24 in 28 of 31 patients in the three-drug group (90 percent), 12 of 28 patients in the indinavir group (43 percent), and none of 30 patients in the zidovudine–lamivudine group. The increase in CD4 cell counts over the first 24 weeks was greater in the two groups receiving indinavir than in the zidovudine–lamivudine group (P<0.01 for each comparison). The changes in the viral load and the CD4 cell count persisted for up to 52 weeks. All the regimens were generally well tolerated.

Conclusions In most HIV-infected patients with prior antiretroviral therapy, the combination of indinavir, zidovudine, and lamivudine reduces levels of HIV RNA to less than 500 copies per milliliter for as long as one year. (N Engl J Med 1997;337:734-9.)

METHODS

Study Patients

Adults who were seropositive for HIV type 1 and who had at least six months of prior zidovudine therapy were screened for enrollment at four sites. They were eligible for the study if they had a serum HIV RNA level of at least 20,000 copies per milliliter (Amplicor HIV Monitor test, Roche Diagnostics Systems, Branchburg, N.J.) at the time of screening and 50 to 400 CD4 cells per cubic millimeter when the values obtained in two determinations at least one week apart were averaged. Additional criteria for enrollment included a hemoglobin level exceeding 9.0 g per deciliter (in men) or 8.5 g per deciliter (in women), a neutrophil count greater than 1000 per cubic millimeter, a platelet count of at least 100,000 per cubic millimeter, a serum creatinine level less than 1.5 times the upper limit of normal, a total bilirubin level in the normal range, and levels of hepatic aminotransferases and alkaline phosphatase less than 2 times the upper limit of normal.

Patients were excluded if they received lamivudine or any HIV-protease inhibitor, if they required maintenance therapy for an opportunistic infection, or if they had received investigational or immunomodulatory drugs within 30 days before entry into the study. Also excluded were pregnant or breast-feeding women, as were patients with active substance abuse, hepatitis B surface an-

From the New York University School of Medicine, New York (R.M.G., C.G., F.T.V.); the University of Pittsburgh and Veterans Affairs Medical Center, Pittsburgh (J.W.M., D.M.); the University of California, San Diego (D.H., D.D.R.); the University of North Carolina, Chapel Hill (J.J.E.); and Merck Research Laboratories, West Point, Pa. (L.J., A.M., E.A.E., J.A.C.). Address reprint requests to Dr. Gulick at NYU Medical Center, Department of Medicine, 550 First Ave., New York, NY 10016.

Other authors were Paul Deutsch, M.D., Ph.D., Daniel Holder, Ph.D., William A. Schleif, M.S., and Jon H. Condra, Ph.D. (all from Merck Research Laboratories, West Point, Pa.).
tigenemia, substantial elevations of hepatic aminotransferases in the prior year, or intolerance to zidovudine. Patients were permitted to take prophylaxis for Pneumocystis carinii pneumonia.

**Study Design**

This was a randomized, double-blind, controlled study of the safety and activity of three antiretroviral regimens. Randomization followed a permuted-block design stratified according to site and CD4 cell count (either 50 to 250 or 251 to 400 cells per cubic millimeter). The planned duration of the double-blind study was 52 weeks, but because there were preliminary findings of antiretroviral activity, the study design was amended to provide open-label therapy with all three drugs after a minimum of 24 weeks of blinded, randomized therapy. This change resulted in periods of blinded, randomized treatment of varying lengths, from 24 weeks to 52 weeks. Only data corresponding to the blinded portion of the study are presented here. All the patients continued to be monitored while they were receiving open-label therapy. The study was approved by the internal review boards at each site, and all the patients gave written informed consent.

**Treatment Regimens**

Eligible patients discontinued their antiretroviral therapy two weeks before entry and were then randomly assigned one of three regimens given orally: 800 mg of indinavir (Crixivan, Merck, West Point, Pa.) every 8 hours; 200 mg of zidovudine (Retrovir, Glaxo-Wellcome, Research Triangle Park, N.C.) every 8 hours combined with 150 mg of lamivudine (Epivir, Glaxo–Wellcome) every 12 hours; or all three drugs at the same doses. The regimens included appropriate matching placebos.

**Assessments**

The patients were assessed weekly for four weeks, every two weeks through week 16, and every four weeks through week 52. At base line and each study visit, the medical history was reviewed, a physical examination was performed, and standardized laboratory tests were conducted. A pregnancy test of serum was performed in eligible women before the study and every four weeks thereafter. Blood samples were collected from a subgroup of patients on day 8 to determine plasma drug concentrations. Patients who discontinued the study were reevaluated two weeks after their last dose of the study drugs. Adverse events were managed by investigators unaware of the treatment assignments, using predetermined guidelines.

**Virologic and Immunologic Studies**

Samples were obtained at screening, at base line, and at each study visit. Serum was processed, stored at −70°C, and assayed later for HIV RNA by a quantitative reverse-transcriptase–polymerase-chain-reaction (PCR) assay (Amplicor test). The lower limit of quantification was 500 RNA copies per milliliter. The assay results were reported as values when there were 500 or more copies per milliliter or as “less than 500 copies per milliliter,” or as “negative” if no amplification signal was detected. An investigational version of an ultrasensitive PCR assay was performed on samples in which the standard assay detected a level of less than 500 copies per milliliter. This assay had a consistent cutoff of detection of approximately 50 RNA copies per milliliter. In the analysis of resistance, viral RNA was extracted from serum, amplified by PCR, and cloned and sequenced by a previously described method. T-lymphocyte subgroups were quantified by flow cytometry.

**Statistical Analysis**

The primary measures of antiretroviral-drug activity were the magnitude and duration of changes in serum HIV RNA and CD4 cell counts over a period of 24 weeks, as summarized by an area-under-the-curve measurement that incorporated the base-line value. All the patients with determinations made at base line and at least once subsequently were included in the analyses. For the purpose of analysis, RNA values reported as “less than 500 copies per milliliter” were considered equivalent to 500 copies per milliliter, and values reported as “negative” were considered equivalent to 250 copies per milliliter. The HIV RNA values underwent a log transformation before analysis. The area under the curve was computed among the treatment groups with an analysis-of-variance model that included the study treatment and a variable defined according to site and CD4 stratum. In calculating the proportion of patients who had HIV RNA levels of less than 50 copies per milliliter by the ultrasensitive investigational assay, we assumed that patients who had at least 500 RNA copies per milliliter by the standard assay had at least 50 copies per milliliter. For each pair of treatments, Fisher's exact test was used to compare the groups with respect to the proportion of patients with clinical nephrolithiasis, severe drug-related adverse events, and clinically significant laboratory abnormalities. A clinically significant laboratory abnormality was considered to be present if a value exceeded the predefined criteria or an abnormality present at base line became worse. The analyses were performed on an intention-to-treat basis. Nominal unadjusted two-sided P values were reported.

**RESULTS**

**Study Patients**

Ninety-seven patients were enrolled in the study from April to December 1995. Initially, 27 patients were enrolled for a four-week analysis of safety; when no serious adverse events occurred, the remaining 70 patients were enrolled. The base-line characteristics of the patients were similar in the three treatment groups (Table 1). Of the 97 patients, 92 were studied on a randomized, blinded basis for 24 weeks, 79 for 36 weeks, and 16 for 52 weeks. The patients switched to open-label three-drug therapy after a median of 41 weeks (range, 24 to 52). Seven patients discontinued the study after 4 to 44 weeks, for various reasons: an adverse event (one patient), loss to follow-up (one), the use of medications prohibited by the protocol (two), and the patient's request (three). There were no significant differences among the treatment groups in the rates of discontinuation (P > 0.35 for each pairwise comparison).

**Pharmacokinetic Analysis**

Plasma concentrations of the study drug were measured in the first 27 patients enrolled in the study. There were no clinically significant pharmacokinetic interactions among the study medications.

**HIV RNA**

Over a 24-week period, serum HIV RNA levels declined in all three groups, with adjusted mean (±SE) decreases (in the area-under-the-curve analysis) of 1.77±0.11 log10 in the three-drug group, 1.24±0.11 log10 in the indinavir group, and 0.83±0.11 log10 in the zidovudine–lamivudine group (Fig. 1). The decrease was significantly greater in the three-drug group than in the other two groups (P<0.001 for each pairwise comparison). In addition, the decrease
in the indinavir group was significantly greater (P = 0.005) than that in the zidovudine–lamivudine group. In the three-drug group there was a median reduction of more than 2 log₁₀ in the HIV RNA level that lasted from week 8 to week 52. In contrast, after initial decreases, the RNA levels increased in both the indinavir and zidovudine–lamivudine groups. Figure 2A shows the proportion of patients in each group who had decreases in HIV RNA levels to less than 500 copies per milliliter. At week 24, 90 percent of the patients in the three-drug group (28 of 31) had levels of less than 500 RNA copies per milliliter, as compared with 43 percent of the indinavir group (12 of 28 patients) and none of 30 patients in the zidovudine–lamivudine group. These proportions were sustained for up to 52 weeks. Figure 2B shows the proportion of patients in each group whose levels decreased to less than 50 copies per milliliter.

Genotypic Analysis

There was no evidence of resistance to lamivudine¹⁹–²¹ at base line. After 24 weeks of therapy, 84 percent of the zidovudine–lamivudine group (26 of 31) had such resistance, and 53 percent (10 of 19) of patients with amplifiable RNA in the indinavir group had mutations conferring resistance to indinavir.¹⁴ At the same time, 26 of 31 serum samples from patients in the three-drug group could not be amplified because of low HIV RNA levels. Of the five patients in that group who had more than 500 RNA copies per milliliter by week 32, all had virus with resistance to lamivudine, and three acquired indinavir-resistance mutations.

CD4 Cell Counts

CD4 cell counts increased during the first 24 weeks of treatment in all the groups, with adjusted mean (±SE) increases (in the area-under-the-curve analysis) of 86.0±11.9 cells per cubic millimeter in the three-drug group, 100.6±12.5 in the indinavir group, and 46.3±12.1 in the zidovudine–lamivudine group (Fig. 3). The increase was significantly greater in the groups assigned to the two regimens containing indinavir than in the zidovudine–lamivudine group (P≤0.01 for each comparison). There

---

**Table 1. Base-Line Characteristics of the Study Patients.**

<table>
<thead>
<tr>
<th>CHARACTERISTIC</th>
<th>ALL PATIENTS (N=97)</th>
<th>THREE DRUGS (N=33)</th>
<th>INDIANAVIR (N=31)</th>
<th>ZIDOVUDINE–LAMIVUDINE (N=33)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex — no. of patients (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>82 (85)</td>
<td>31 (94)</td>
<td>24 (77)</td>
<td>27 (82)</td>
</tr>
<tr>
<td>Female</td>
<td>15 (15)</td>
<td>2 (6)</td>
<td>7 (23)</td>
<td>6 (18)</td>
</tr>
<tr>
<td>Mean (±SD) age — yr</td>
<td>40.1±8.5</td>
<td>41.4±7.9</td>
<td>40.2±8.6</td>
<td>38.7±8.9</td>
</tr>
<tr>
<td>Race or ethnic group — no. of patients (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White, non-Hispanic</td>
<td>71 (73)</td>
<td>26 (79)</td>
<td>22 (71)</td>
<td>23 (70)</td>
</tr>
<tr>
<td>Black</td>
<td>10 (10)</td>
<td>2 (6)</td>
<td>5 (16)</td>
<td>3 (9)</td>
</tr>
<tr>
<td>Hispanic or Latino</td>
<td>12 (12)</td>
<td>3 (9)</td>
<td>2 (6)</td>
<td>7 (21)</td>
</tr>
<tr>
<td>Other</td>
<td>4 (4)</td>
<td>2 (6)</td>
<td>2 (6)</td>
<td>0</td>
</tr>
<tr>
<td>Prior zidovudine therapy — mo</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td>29.7</td>
<td>28.2</td>
<td>32.2</td>
<td>31.2</td>
</tr>
<tr>
<td>Range</td>
<td>5.1–91.6</td>
<td>6.3–91.6</td>
<td>5.1–87.3</td>
<td>6.2–69.1</td>
</tr>
<tr>
<td>Prior AIDS-defining illness — no. of patients (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td>13 (13)</td>
<td>5 (15)</td>
<td>5 (16)</td>
<td>3 (9)</td>
</tr>
<tr>
<td>CD4 count — cells/mm³</td>
<td>50–250</td>
<td>75 (77)</td>
<td>25 (76)</td>
<td>24 (77)</td>
</tr>
<tr>
<td>Median</td>
<td>144</td>
<td>133</td>
<td>155</td>
<td>144</td>
</tr>
<tr>
<td>Range</td>
<td>35–480</td>
<td>35–433</td>
<td>51–480</td>
<td>35–400</td>
</tr>
<tr>
<td>Serum HIV RNA Copies/ml</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td>43,190</td>
<td>41,900</td>
<td>39,910</td>
<td>44,040</td>
</tr>
<tr>
<td>Log₁₀ copies/ml</td>
<td>4.64</td>
<td>4.62</td>
<td>4.60</td>
<td>4.64</td>
</tr>
</tbody>
</table>

*Because of rounding, percentages do not total 100 in every case.
†These drugs included didanosine, zalcitabine, and stavudine.
‡Patients were stratified on the basis of the mean of two CD4 cell counts obtained before the start of the study.
§For one patient in the three-drug group, HIV RNA was not measured before the study treatment began.
was no significant difference between the three-drug group and the indinavir group over the first 24 weeks (P = 0.36). The CD4 cell count in each group remained at approximately the same level from week 24 to week 52.

**Adverse Events**

The study treatments were generally well tolerated for up to 52 weeks (Table 2). One patient withdrew from the study because of an adverse event (nausea). Elevated bilirubin levels and clinical nephrolithiasis, defined as pain in the flank with or without hematuria or the passage of a stone or gravel in the urine, occurred more often in the patients receiving indinavir. There were no other significant differences among the groups in the occurrence of severe, drug-related clinical events or clinically important laboratory abnormalities. One new AIDS-defining illness (presumptive candida esophagitis) occurred in a patient randomly assigned to zidovudine and lamivudine. There were no deaths among the study patients.

**DISCUSSION**

The three-drug combination of indinavir, zidovudine, and lamivudine reduced the viral load in serum to less than 500 copies per milliliter for up to one year in more than 80 percent of the HIV-infected patients we studied, all of whom had prior antiretroviral therapy. Most patients in the three-drug group whose HIV RNA levels were reduced to less than 500 copies per milliliter also had less than 50 RNA copies per milliliter when the ultrasensitive investigational assay was used. The sustained response in HIV RNA levels with the three-drug therapy was superior to that with either indinavir monotherapy or the combination of zidovudine and lamivudine.
No prior antiretroviral regimen has produced the marked, sustained decreases in viral load achieved with this three-drug combination.

The continued suppression of HIV RNA levels for one year without evidence of the emergence of resistant virus suggests that there was little, if any, continuing HIV replication in the patients receiving three-drug therapy. At 24 weeks, high levels of resistance to lamivudine had developed in most of the patients receiving zidovudine and lamivudine,19-21 and over half the patients with amplifiable HIV RNA who were receiving indinavir alone had resistance to indinavir.14 In contrast, most patients treated with the three-drug combination provided serum samples from which HIV RNA could not be amplified, implying that the virus continued to be susceptible. The durable antiretroviral activity of the three-drug regimen appears to result directly from the inability of resistant virus to emerge.

If there is to be long-term control of HIV infection, the goal of antiretroviral therapy should be the sustained, complete suppression of HIV replication and the prevention of resistance to the antiretroviral drugs. Without complete viral suppression, antiretroviral regimens will probably select for drug-resistant mutants, leading to the failure of therapy. The patients we studied had taken neither lamivudine nor any protease inhibitor before entering the study. When lamivudine and indinavir were introduced concurrently as part of the three-drug regimen, they had potent antiretroviral activity, thus preventing the development of resistance to lamivudine, which is typically seen within weeks after the start of lamivudine treatment, either alone or with zidovudine.22,23 Patients previously treated with lamivudine or a protease inhibitor may not have similar sustained benefits with this three-drug regimen.

The reasons for the rebound of serum HIV RNA levels in a few patients taking the three drugs are not clear. Among the five patients in the three-drug group who had more than 500 HIV RNA copies per milliliter by week 32, all had resistance to lamivudine and three had resistance to indinavir. One of these five patients discontinued therapy prematurely, and three others reported intermittent adherence to the study regimen. In the fifth patient, the HIV RNA level declined markedly but then increased, with the concomitant development of resistance to both lamivudine and indinavir. The rebound in HIV RNA levels did not appear to be associated with base-line resistance to zidovudine, base-line polymorphisms of viral-protease residues, or the level of HIV RNA at entry.

This study was designed to compare the treatment groups with respect to viral load and CD4 cell responses, not clinical end points. Recent evidence from natural-history studies and clinical trials links viral load and clinical outcome.1,2,4,5,24-29 These studies suggest that the sustained reductions of HIV RNA we observed will probably translate into delayed progression to AIDS and prolonged survival.

The dissociation between the marked decreases in viral load and the incomplete restoration of CD4 cell counts in the three-drug group remains unexplained. Some patients may have ongoing, slower increases in CD4 cell counts after six months of therapy. In patients with autoimmune disease or cancer who receive intensive radiation therapy or chemotherapy, CD4 cell counts recover slowly and may take three years or more to reach normal levels.30,31 Further study is needed to determine what level of restoration of CD4 cell number and function can ultimately be attained with the three-drug regimen. It remains to be seen whether the immune system can be fully reconstituted even when regimens that achieve maximal HIV suppression are used.

All the study treatments were generally well tolerated, with only a single patient discontinuing the blinded portion of the study because of an adverse event. As expected, the use of indinavir was associated with episodes of clinical nephrolithiasis and asymptomatic increases in indirect bilirubin. The pro-
portion of patients who met our definition of nephrolithiasis was higher in this study than has previously been observed. To facilitate long-term compliance with drug regimens, it is essential that the antiretroviral drugs be well tolerated.

In summary, the antiretroviral-drug combination of indinavir, zidovudine, and lamivudine reduced HIV RNA levels to less than 500 copies per milliliter in most HIV-infected patients previously treated with zidovudine for as long as one year. This suggests that profound suppression of HIV replication inhibits the emergence of drug-resistant virus and that such inhibition should be an important goal in the long-term treatment of HIV infection. A regimen that falls short of maximal viral suppression will probably be accompanied by the emergence of drug resistance and by ultimate clinical failure. The results of this study support a new standard for the evaluation of antiretroviral therapies and suggest a new paradigm for the treatment of HIV disease.

Supported by contracts (P30-AI-27742, U01-AI-27665, N01-AI-27670, N01-AI-38858, N01-AI-36214, N01-AI-29164, M01-RR00056, M01-RR00096, M01-RR00406) with the National Institutes of Health and by grants from Merck Research Laboratories.


We are indebted to the patients who volunteered for the study; to our study coordinators, Candida Talabouco, R.N., Richard Hutt, R.N., Nancy Mantz, B.S.N., Carl Garrubba, P.A., Kathy Nuffer, R.N., and Janet Kozel, P.A.; to Charles Lin for performing pharmacokinetic assays; to Andrew Sterrett for statistical support; to Malathi Sivasubramani, M.S., Donald Graham, M.S., Robert Danovitch, Ph.D., Tao Yang, M.S., and Donna Laird, B.S., for technical virologic support; to Olivia Ortiz, M.D.; and to James Rooney, M.D., Glaxo–Wellcome, for providing zidovudine and lamivudine.

REFERENCES


8. Vees JE, Dorsey BD, Schleif WA, et al. L-735,524: an orally bioavail-